Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently approved by the FDA, which was widely expected, but the initial daily price of $31 is a bit above the threshold of $8 per day the firm’s key opinion leaders cites as the limit to ensure broad uptake, the analyst tells investors. Journavx’s value proposition as an opioid alternative, however, should not be ignore and could still drive uptake in acute pain.
-
Leverage the power of TipRanks’ Smart Score a data driven tool to help you uncover top performing stocks and make informed investment decisions.
-
Monitor your stock picks and compare them to top Wall Street Analysts’ recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
